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severe (grade III), on the basis of two clinical factors, the on-
set of organ dysfunction and the response to the initial medi-
cal treatment. “Severe (grade III)” acute cholangitis is defi ned 
as acute cholangitis accompanied by at least one new-onset 
organ dysfunction. “Moderate (grade II)” acute cholangitis is 
defi ned as acute cholangitis that is unaccompanied by organ 
dysfunction, but that does not respond to the initial medical 
treatment, with the clinical manifestations and/or laboratory 
data not improved. “Mild (grade I)” acute cholangitis is de-
fi ned as acute cholangitis that responds to the initial medical 
treatment, with the clinical fi ndings improved.
Key words Cholangitis · Diagnosis · Severity of illness index · 
Guidelines
Introduction
The pathogenesis of acute cholangitis is biliary infection 
associated with partial or complete obstruction of the 
biliary system caused by any of various etiologies 
including choledocholithiasis, benign and malignant 
strictures, biliary-enteric anastomotic malfunction, and 
indwelling biliary stent malfunction. Biliary infection 
alone does not cause clinical cholangitis unless biliary 
Abstract
Because acute cholangitis sometimes rapidly progresses to a 
severe form accompanied by organ dysfunction, caused by the 
systemic infl ammatory response syndrome (SIRS) and/or sep-
sis, prompt diagnosis and severity assessment are necessary 
for appropriate management, including intensive care with 
organ support and urgent biliary drainage in addition to medi-
cal treatment. However, because there have been no standard 
criteria for the diagnosis and severity assessment of acute 
cholangitis, practical clinical guidelines have never been es-
tablished. The aim of this part of the Tokyo Guidelines is to 
propose new criteria for the diagnosis and severity assessment 
of acute cholangitis based on a systematic review of the litera-
ture and the consensus of experts reached at the International 
Consensus Meeting held in Tokyo 2006. Acute cholangitis can 
be diagnosed if the clinical manifestations of Charcot’s triad, 
i.e., fever and/or chills, abdominal pain (right upper quadrant 
or epigastric), and jaundice are present. When not all of the 
components of the triad are present, then a defi nite diagnosis 
can be made if laboratory data and imaging fi ndings support-
ing the evidence of infl ammation and biliary obstruction are 
obtained. The severity of acute cholangitis can be classifi ed 
into three grades, mild (grade I), moderate (grade II), and 
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obstruction raises the intraductal pressure in the bile 
duct to levels high enough to cause cholangiovenous 
or cholangiolymphatic refl ux.1 Thus, acute cholangitis 
progresses from local biliary infection to the systemic 
infl ammatory response syndrome (SIRS), and advanced 
disease leads to sepsis with or without organ 
dysfunction.
Prior to the 1970s the mortality rate of patients with 
acute cholangitis was reported to be over 50%,2,3 but 
advances in intensive care, new antibiotics, and biliary 
drainage dramatically reduced the mortality rate to less 
than 7% by the 1980s.4,5 However, even in the 1990s the 
reported mortality rates in severe cases still ranged from 
11% to 27%,6–8 and even now the severe form of acute 
cholangitis remains a fatal disease unless appropriate 
management is instituted.
The clinical diagnosis of acute cholangitis is made on 
the basis of the clinical fi ndings, such as Charcot’s triad,9 
in combination with the laboratory data and imaging 
fi ndings, and severity assessment is important because 
urgent biliary drainage is essential in “severe” cases. 
However, no standard criteria for the diagnostis and 
severity assessment of acute cholangitis have ever been 
established. In this portion of the Tokyo Guidelines, we 
propose diagnostic criteria and severity assessment cri-
teria for acute cholangitis based on a review of the lit-
erature and the consensus of experts reached at the 
International Consensus Meeting for the Management 
of Acute Cholecystitis and Cholangitis, held on April 
1–2, 2006, in Tokyo.
Diagnostic criteria for acute cholangitis
A variety of different names and defi nitions of acute 
cholangitis are found in the literature, depending on the 
authors.6,8,10–17 Some authors defi ned acute cholangitis 
based on clinical sign’s such as Charcot’s triad (fever 
and/or chills, abdominal pain, and jaundice),6,16–17 while 
others emphasized the presence of biliary obstruction 
or the properties of the bile (suppurative cholangi-
tis),10,13–14 as a result, there are no standard diagnostic 
criteria for acute cholangitis. The clinical information 
used to establish the diagnosis of acute cholangitis in-
cludes a history of biliary disease, symptoms and signs, 
laboratory data, and imaging fi ndings.
Clinical context and manifestations
A history of biliary disease suggests a clinical diagnosis 
of cholangitis in patients who present with clinical mani-
festations such as fever, abdominal pain, and jaundice. 
Patients with a history of gallstone disease, previous 
biliary surgery, or the insertion of a biliary stent are 
more likely to develop biliary infection.
Clinical manifestations are an important factor in 
making the diagnosis of acute cholangitis. In 1877,9 
Charcot was the fi rst to describe the clinical triad of 
fever, jaundice and abdominal pain as a clinical mani-
festation of acute cholangitis, and in 1959, Reynolds and 
Dragan18 were the fi rst to describe a severe form of 
cholangitis that included Charcot’s triad plus septic 
shock and mental status change (Reynold’s Pentad). 
Table 1 summarizes the incidence of each clinical mani-
festation reported in the literature.6,8,10–17 Fever and ab-
dominal pain are the most frequently observed clinical 
manifestations in acute cholangitis, with an incidence of 
each of up to 80% or more, whereas jaundice is ob-
served in 60%–70% of cases. The incidence of Charcot’s 
triad is reported in not more than 72% (range, 15.4% 
to 72%) of patients with acute cholangitis, and 
Reynolds’ pentad is extremely rare, reported in only 
3.5%–7.7% of the patients.
Laboratory data
Laboratory data indicative of infl ammation (e.g., leuko-
cytosis and an elevated C-reactive protein [CRP] level), 
and evidence of biliary stasis (e.g., hyperbilirubinemia, 
elevation of biliary enzymes and liver enzymes) are fre-
quently seen in patients with acute cholangitis, and 
such laboratory fi ndings support the diagnosis. Table 2 
summarizes the positive rate for various blood tests 
in patients with acute cholangitis reported in the 
literature.5,12,13,17,19–21
Imaging fi ndings
It is usually impossible to identify evidence of bile infec-
tion itself by imaging modalities. Imaging evidence of 
biliary dilatation (evidence of biliary obstruction) and/
or the etiology of the underlying disease (tumor, gall-
stones, stent-related, etc.) can support the clinical diag-
nosis of cholangitis.
Diagnostic criteria for acute cholangitis
Table 3 shows the diagnostic criteria for acute cholan-
gitis that were fi nally adopted by the Organizing Com-
mittee. The basic concepts of the criteria are as follows: 
(1) Charcot’s triad is a defi nite diagnostic criterion for 
acute cholangitis, (2) if a patient does not have all the 
components of Charcot’ s triad (acute cholangitis is sus-
pected), then defi nite diagnosis can be achieved if both 
an “infl ammatory response” and “biliary obstruction” 
are demonstrated by the laboratory data (blood tests) 
and imaging fi ndings.
Outcome of the Tokyo Consensus Meeting
More than 90% of the participants at the Tokyo Con-
sensus Meeting agreed that the four criteria of: (1) a 
54 K. Wada et al.: Diagnosis of acute cholangitis
Table 1. Incidence of clinical manifestation of acute cholangitis
   Charcot’s Fever Jaundice Abdominal Reynold’s Shock Disturbed
Author Disease n triad (%) % % pain (%) pentad (%) % consciousness (%)
Csendes10 ASC 51 22  38.7 65.4  92.2   7  7.2
   2
Thompson11 AC 66 About 60 100 66  59   7  9
Gigot12 AC 41 72    3.5  7.8  7
   2
Boey13 AC 99 69.7  93.9 78.8  87.9 5.1 16.2 16.2
 SC 14     7 57 28
 NonSC 72     4  8 12
O’Connor14 AC 65 60    7.7 32 14
 SC 19 53    5 47 11
 NonSC 46 63    9 26 15
Lai6 Severe AC 86 56  66 93  90  64
Haupert15 ASC 13 15.4 100 61.5 100 7.7 23.1  7.7
Welch16 ASC  5 50  80 60    0 20
 AOSC 15 50  88 67   33 27
Saharia17 AC 78  100 61.5 100   5.1
Chijiiwa8 AOSC 27   63.0 70.3  96.3  25.9 22.2
AC, acute cholangitis; SC, suppurative cholangitis; AOSC, acute obstructive suppurative cholangitis
Table 2. Positive rates for blood tests in acute cholangitis
Item Positive rate (%) No. of cases Author
WBC >10 000/mm3  79 449 Gigot12
  63  78 Saharia17
  82  71 Boey13
Total bilirubin ↑  91  78 Saharia17
  78  74 Boey13
ALP ↑   93 449 Gigot JF5
  92  72 Saharia17
  74  74 Boey13
AST ↑  93  45 Saharia17
ALT ↑  97  35 Saharia17
AST or ALT ↑  57  74 Boey13
Prolonged prothrombin time  26  74 Boey13
Amylase ↑   7  74 Boey13
  35  54 Boey13
Creatinine 1.5 mg/d  16 125 Tai5
CA19-9 ↑  28  25 Ker19
 100   7 Albert20
Endotoxin ↑  36  11 Kanazawa21
WBC, white blood cells; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CA 19-9, carbohydrate 
antigen 19-9
Table 3. Diagnostic criteria for acute cholangitis
A. Clinical context and clinical manifestations 1. History of biliary disease
 2. Fever and/or chills
 3. Jaundice
 4. Abdominal pain (RUQ or upper abdominal)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
B. Laboratory data 5. Evidence of infl ammatory responsea
 6. Abnormal liver function testsb
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
C. Imaging fi ndings 7. Biliary dilatation, or evidence of an etiology (stricture, stone, stent etc)
Suspected diagnosis  Two or more items in A
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Defi nite diagnosis (1) Charcot’s triad (2 + 3 + 4)
 (2) Two or more items in A + both items in B and item C
a Abnormal WBC count, increase of serum CRP level, and other changes indicating infl ammation
b Increased serum ALP, r-GTP (GGT), AST, and ALT levels
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history of biliary disease, (2) the clinical manifestations, 
(3) laboratory data indicative of the presence of infl am-
mation and biliary obstruction, and (4) imaging fi ndings 
indicative of biliary obstruction and/or evidence of 
etiology were suitable making the diagnosis of acute 
cholangitis.
Severity assessment of acute cholangitis
Patients with acute cholangitis may present with any-
thing from a mild, self-limited illness to a severe, poten-
tially life-threatening illness. Most cases respond to 
initial medical treatment consisting of general support-
ive therapy and intravenous antibiotics, but some cases 
do not respond to medical treatment, and the clinical 
manifestations and laboratory data do not improve. 
Such cases may progress to sepsis, with or without organ 
dysfunction, requiring appropriate management that in-
cludes intensive care, organ-supportive care, and urgent 
biliary drainage, in addition to medical treatment.
Severity assessment criteria
Table 4 summarizes the risk factors reported in the 
literature for poor outcome in patients with acute 
cholangitis.2,3,6,10,12,13,15,22–24 Organ dysfunction is the 
most common predictor of a poor outcome. On the 
other hand, based on the pathophysiology, “severe” 
acute cholangitis can also be defi ned as that which 
accompanies organ dysfunction caused by sepsis. 
Thus, “the onset of organ dysfunction” is an important 
factor in the defi nition of severe (grade III) acute 
cholangitis.
Another factor for the severity assessment of acute 
cholangitis is “response to initial medical treatment”; 
treatment consisting of general supportive care and 
antibiotics should be instituted as soon as possible 
for all patients who are diagnosed with acute cholan-
gitis. Patients diagnosed with acute cholangitis that 
is not complicated by organ dysfunction, who did not 
respond to medical treatment and who continue to 
have SIRS and/or sepsis require additional treatment 
that includes either a change of antibiotic or biliary 
drainage. The severity of such cases is classifi ed as mod-
erate (grade II). Patients who respond to medical treat-
ment and whose clinical manifestations and laboratory 
data improve are classifi ed as having mild (grade I) 
disease. Table 5 and Table 6 show the concepts 
and criteria for the severity assessment of acute 
cholangitis.
Table 4. Prognostic factors in acute cholangitis
Prognostic factor Positive value References
Related to organ dysfunction
 Shock  2,10,13
 Mental confusion  2,10
 Elevated serum creatinine >1.5–>2.0 mg/dl 3,10,12,22
 Elevated BUN >20–>64 mg/dl 10,12,24
 Prolonged prothrombin time >1.5–>2.0 s 10,23
 Hyperbilirubinemia >2.2–>10 mg/dl 2,5,6,10,13,22–24
 Reduced platelet count <10 × 104–<15 × 104/mm3 3,6,24
Unrelated to organ dysfunction
 High fever  >39 °C–>40 °C 2,13
 Leukocytosis  >20 000 /mm3 2,3
 Bacteremia  3,22
 Endotoxemia  3
 Hypoalbuminemia <3.0 mg/dl 6,23,24
 Liver abscess  12
 Medical comorbidity  10,12,15,24
 Elderly patient >75 Years old 10,12,24
 Malignancy as etiology  12,22
Table 5. Criteria for severity assessment of acute cholangitis
 Severity of acute cholangitis
 Mild Moderate Severe
Criterion (grade I) (grade II) (grade III)
Onset of organ dysfunction No No Yes
Response to initial medical treatmenta Yes No No
a Consisting of general supportive care and antibiotics
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Outcome of the Tokyo Consensus Meeting
More than 70% of the participants at the Tokyo 
Consensus Meeting agreed that the severity of acute 
cholangitis should be divided into three grades — 
mild (grade I), moderate (grade II), and severe (grade 
III). To stratify acute cholangitis into the three grades, 
two different criteria were necessary, and it was decided 
to use “onset of organ dysfunction” and “response to 
the initial medical treatment” as criteria for the severity 
assessment of acute cholangitis (Table 5).
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Discussion at the Tokyo Consensus Meeting
Diagnostic criteria for acute cholangitis
“Acute cholangitis” is a clinical diagnosis. A defi nite 
diagnosis cannot be made on the basis of the results of 
any single test. The diagnosis of acute cholangitis is 
made on the basis of: (1) a history of biliary disease, (2) 
the clinical manifestations, (3) laboratory data that in-
dicate the presence of infl ammation and biliary obstruc-
tion, and (4) imaging fi ndings that indicate biliary 
obstruction. More than 90% of participants at the In-
ternational Consensus Meeting agreed that these four 
criteria were suitable for making the diagnosis of acute 
cholangitis (consensus was reached).
In terms of the clinical context and manifestations, a 
history of biliary disease and the clinical presentation 
are important factors in reaching the diagnosis. A his-
tory of biliary disease, such as gallstones, a history of 
previous biliary surgery, and having an indwelling bili-
ary stent play an important role in making the diagnosis, 
as agreed upon by many participants at the Consensus 
Meeting. The more important clinical manifestations 
are clinical signs, such as Charcot’s triad (fever and/or 
chills, abdominal pain, and jaundice). According to the 
literature, 50%–70% of acute cholangitis patients pres-
ent with Charcot’s triad, meaning that more than one-
third of acute cholangitis patients do not present with 
all the components of Charcot’s triad. The laboratory 
data and imaging fi ndings can provide evidence to sup-
port the diagnosis in patients who have clinical manifes-
tations of acute cholangitis but who do not show all the 
components of Charcot’s triad (refer to Table 3).
Severity assessment criteria for acute cholangitis
A systematic review of the literature revealed that there 
were no standard criteria for either the diagnosis or se-
verity assessment of acute cholangitis. Some authors 
have defi ned acute cholangitis associated with Reyn-
old’s pentad (Charcot’s triad plus “shock” and “distur-
bance of consciousness”) or organ dysfunction as 
“severe”, while others have referred to it as “toxic chol-
angitis” or “acute obstructive suppurative cholangitis 
(AOSC)”. A proposal that the onset of dysfunction of 
at least one organ be used as the criterion for severe 
(grade III) disease was supported by more than 90% of 
the panelists at the International Consensus Meeting 
(consensus was reached).
There was some argument about whether the score 
on an acute physiology scoring system, such as Acute 
physiology and chronic health evaluation (APACHE 
II) score or a multiple organ dysfunction scoring system, 
such as Marshall’s system, or sepsis-related organ fail-
ure assessment (SOFA) system should be used as a 
criterion for severe (grade III) acute cholangitis. The 
principal advantage of these scoring systems is that they 
provide gradations of severity. The APACHE II system 
has been validated, especially for critical care patients, 
including patients with sepsis, and acute cholangitis can 
be interpreted as a subset of sepsis. The disadvantage 
of these scoring systems is that the scores are sometimes 
troublesome to calculate, and critically speaking, they 
have not been satisfactorily validated in patients with 
acute cholangitis. The vote on this argument showed 
that 37.8% of the panelists supported the use of 
APACHE II and 62.2% did not. As a result of this vote, 
the chairmen of this session, Drs. Yoshifumi Kawarada 
(Japan) and Henry Pitt (USA), proposed to remit the 
fi nal decision on whether or not APACHE II should be 
included as a criterion for severe (grade III) acute chol-
angitis to the Organizing Committee, and this proposal 
was approved by the audience.
After the meeting, the Organizing Committee decid-
ed not to include the use of the APACHE II score as a 
criterion for the defi nition of severe (grade III) acute 
cholangitis, and we established the criteria by evaluat-
ing the presence or absence of the dysfunctions of six 
major organs/systems (refer to Table 6).
Deciding on the criteria for the assessment of acute 
cholangitis as moderate was the hardest part of this ses-
sion. More than 70% of the participants agreed that a 
middle category of severity — moderate (grade II) — 
was necessary for acute cholangitis (consensus was 
reached).
The original defi nition of moderate (grade II) acute 
cholangitis was “acute cholangitis that requires biliary 
drainage but is not complicated by organ dysfunction.” 
However, more than 80% of the participants voted 
against the need for biliary drainage as a criterion be-
cause it is a therapeutic intervention that should be 
selected only after the severity assessment has been 
completed. Thus, another criterion was needed in order 
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to stratify acute cholangitis into three grades. Other 
criteria for assessing acute cholangitis as moderate 
(grade II) were suggested by the audience. The most 
accepted criterion during the discussion was “resistance 
to initial treatment”, with some others being “recur-
rence of symptoms” and “SIRS”. The chairmen of this 
session also proposed to remit the fi nal decision to the 
Organizing Committee, and this proposal was approved 
by the audience.
After the Meeting, the Organizing Committee con-
cluded that the criterion for assorting into moderate 
(grade II) and mild (grade I) acute cholangitis should 
be “response to initial medical treatment consisting of 
general supportive care (intravenous fl uid) and antibi-
otics,” i.e., acute cholangitis that responds to medical 
treatment is defi ned as mild (grade I) acute cholangitis, 
whereas acute cholangitis that does not respond to the 
initial medical treatment but does not have organ dys-
function is defi ned as moderate (grade II) acute cholan-
gitis (refer to Tables 5 and 6). No specifi c data or fi ndings 
were adopted as criteria, because it is impossible to 
predict the need for biliary drainage based on the labo-
ratory data or other fi ndings. It was therefore concluded 
that we considered that it is important to stratify acute 
cholangitis as “severe” or “non-severe” at the time 
of diagnosis. Patients with the former require urgent 
biliary drainage in addition to general and organ-
supportive treatment, while patients with the latter 
should be monitored to determine whether they 
respond to the initial medical treatment.
